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I have written three previous reviews on drug-
induced immune hemolytic anemia (DIIHA) for this
journal.1–3 The last one was written in 1994.3 This year,
I would like to review what has happened in the last
decade.
When Dr. Petz and I published the first edition of
our book (Acquired Immune Hemolytic Anemias) in
1980,4 we found that there was reasonable evidence to
support that about 30 drugs could cause DIIHA. One
drug,methyldopa,was by far the most common drug to
do this. Almost 70 percent of DIIHAs referred to our
laboratory in the 1970s were associated with methyl-
dopa. Antibodies associated with methyldopa were
drug-independent and the patients showed all the
serologic and hematologic characteristics of “warm
type” autoimmune hemolytic anemia (WAIHA).
Twenty-three percent of the DIIHAs were associated
with high-dose IV penicillin therapy; only about 10
percent of DIIHAs were associated with other drugs
(e.g., quinine, rifampicin, and hydrochlorothiazide).
In the next 20 years, methyldopa and high dose IV
penicillin were used less and less; we have not seen a
case of DIIHA associated with these two drugs for
many years. By 1994 about 71 drugs had been
implicated in DIIHA.5 Recently published results
reflect a changing picture in the spectrum of DIIHA in
the last 25 years.6,7 There are now approximately 100
drugs associated with DIIHA (see Table 1), and
methyldopa and penicillin have been replaced by a
single group of drugs, the cephalosporins (93% of
cases), with cefotetan alone accounting for 83 percent
of the DIIHAs we have encountered in the last 10
years. Table 2 shows the drugs causing DIIHA that we
have encountered in the past 26 years (1978–2003).
Methyldopa is probably underrepresented as, by 1978,
cases of autoimmune hemolytic anemia (AIHA) in
patients taking methyldopa were not usually sent to
specialist laboratories such as ours for investigation.
Because of these statistics, I will be emphasizing
the cephalosporins in this review.
Cephalosporin-Induced Immune Hemolytic
Anemia
There are about 70 individual published case
reports of cephalosporin-induced immune hemolytic
anemia (CIIHA),8–64 but many more are contained in
reviews or tables without case histories65–67 (see Table
3). Most patients have had severe hemolytic anemia
(HA), often with intravascular lysis, and 40 percent
were associated with fatal HA. It is not known if this is
the tip of the iceberg and there are many more cases 
of milder HA or positive DATs that are not reported;
the same questions apply to cephalosporin-induced
thrombocytopenia. Tables 4 and 5 summarize the
clinical and serologic findings associated with
cefotetan- and ceftriaxone-induced immune HA. It
should be emphasized that cefotetan antibodies always
react with cefotetan-coated RBCs and almost always
react with untreated RBCs in the presence of cefotetan
(“immune complex” method), and about one-third will
react with RBCs without the presence of drug (i.e.,will
appear to be autoantibodies). The latter findings can
lead to problems in the blood transfusion service. If a
patient receives cefotetan prophylactically for surgery,
receives a blood transfusion during or after surgery,and
then develops HA 7 to 10 days afterwards, a delayed
hemolytic transfusion reaction is often suspected. The
hematologic findings can also mimic AIHA. If the HA is
due to cefotetan, the DAT will be positive (although we
have reported one case where the DAT was negative).68
Sometimes the serum will react with all untreated
RBCs, mimicking an alloantibody to a high-frequency
antigen, or a mixture of alloantibodies or autoantibody,
and many hours may be wasted investigating these
possibilities. If there is a history of cefotetan
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administration, I recommend testing an eluate from the
patient’s RBCs against untreated and cefotetan-coated
RBCs to help with the differential diagnosis. If the
eluate is reactive with cefotetan-treated RBCs and not
the same untreated RBCs, the diagnosis is obvious.
Unfortunately, in about 15 percent of cases we have
studied, the eluate also reacted with untreated RBCs
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sulbactam sodium (e.g., in Unasyn)
sulindac
sulfonamides
sulfonylurea derivatives (e.g., chlorpropamide)
suprofen
suramin











*Drugs in publications containing reasonable evidence for an immune etiology were the only drugs included (many more are in the literature).
Table 2. Drugs associated with DIIHA investigated at American Red
Cross Blood Services, Los Angeles, in the last 26 yrs.
(1978–2003)























Table 3. Cephalosporins reported to cause immune hemolytic anemia
(up to 2003)
Drug Number of case reports References
cephalothin 5 8–11
cefazolin 1 11
cephalexin 2 12, 13
cefamandole 1 14






ceftazidime 2 63, 64
Total 75
*Many other cases are reported, without individual case reports, in references 65 (43
cases) and 66 (85 cases)
140 I M M U N O H E M A T O L O G Y, V O L U M E  2 0 , N U M B E R  3 , 2 0 0 4
(Arndt, Leger, Garratty, unpublished observations). The
diagnosis may then rest on the presence of a high-titer
(> 100) cefotetan antibody in the patient’s serum.
Some illustrative case histories associated with such
problems have been published in this journal.36
Technical hints when investigating CIIHA
1. When preparing cefotetan-coated RBCs, use a
buffer with a pH of 6 to 7 (or normal saline) instead
of the high pH buffer (pH 8 to 10) used for
preparation of penicillin-coated RBCs.69 The lower
pH does not reduce sensitivity but does reduce
nonspecific uptake of protein leading to falsely
positive antihuman globulin (AHG) tests. Some
investigators have suggested that drugs can be
solubilized more efficiently in 1% albumin.70 We do
not advise this when testing for cefotetan
antibodies, as albumin can cause reduced binding
of drug to drug-treated RBCs.71
2. Most individuals, including healthy donors, have
antibodies in their sera that can directly agglutinate
cefotetan-coated RBCs.72 In addition,almost all sera
(including those from healthy individuals) will
yield positive IATs with cefotetan-treated RBCs.
When testing a patient’s serum with cefotetan-
coated RBCs, dilute the serum 1 in 100 in saline.36
This will avoid agglutination and nonspecific
protein uptake onto cefotetan-treated RBCs;
clinically significant antibodies always have titers 
> 100 (e.g., in the thousands). Some texts still
recommend a dilution of 1 in 20, which is what we
recommended when using cephalothin-coated
RBCs. We have found that 1 in 20 is sufficient to
exclude nonspecific adsorption of proteins by
cefotetan-treated RBCs, but is not sufficient to
exclude agglutination of cefotetan-treated RBCs by
about 10 percent of sera (even from healthy
donors).72
3. The lesson to be learned by the above is: never
report cefotetan antibodies to be present based on
reactions of undiluted sera. As with penicillin-
induced immune HA,the diagnosis should be based
on an eluate from the patient’s DAT-positive RBCs
reacting with cefotetan-coated RBCs, but not
untreated RBCs; unlike penicillin, the cefotetan
antibody in the eluate may sometimes react with
untreated RBCs (see reference 65). Another
problem is that the last wash of the patient’s RBCs
may be reactive.73 The presence of a high titer (>
100) cefotetan antibody in the serum confirms the
diagnosis.
4. Ceftriaxone-coated RBCs cannot be made, thus the
serologic diagnosis is based on the results of the
“immune-complex” method. Nonspecific ad-
sorption of proteins is not a problem by this
method, thus undiluted sera can be used.
Sometimes, positive reactions are only obtained by
using enzyme-treated RBCs, or metabolites of the
drug (e.g., in the presence of urine from a patient
taking ceftriaxone).29,32,35
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Table 4. Clinical* and serologic** findings associated with cefotetan-
induced IHA
•  Approx. 80 percent of patients received cefotetan for surgery; usually a
single dose of 2 g was used.
•  A history of previous cefotetan therapy was not common.
•  HA was obvious in less than 1 day to 13 days after receiving cefotetan.
Only two patients had HA in < 1 day; the mean of the other 29 was 9
days.
•  Patients’ nadir Hb after receiving cefotetan = 2.6 g/dL (mean = 4.8 g/dL).
•  Most patients had signs of intravascular lysis (hemoglobinemia/
hemoglobinuria).
•  Fatal HA and renal failure occurred in 19 percent of patients.
•  Patients always had a positive DAT:
–  100% had RBC-bound IgG
–  86% had RBC-bound C3
–  44% had RBC-bound IgA
–  7.4% had RBC-bound IgM
•  All sera agglutinated cefotetan-treated RBCs (median titer 512) and
reacted by IAT (median titer 16,000); all normal sera also reacted with
the cefotetan-treated RBCs, but were nonreactive when diluted ≥ 1 in
100.
•  All but one of the sera reacted with untreated RBCs in the presence of
cefotetan (“immune complex” mechanism).
•  33 percent and 40 percent of sera reacted with RBCs without drug
being present, with saline-suspended RBCs or in the presence of PEG,
respectively.65
*Clincal data from references 38–40, 42–49, 50–53, 56, 57
** Serologic data from reference 65
Table 5. Clinical and serologic findings associated with ceftriaxone-
induced IHA
•  HA is more acute and severe in children compared to adults. In
children, HA started 5 minutes to 7 days after receiving drug; for six
children there was a mean of 27 minutes and for three children a mean
of 6 days.22,26–29,31,34,37 In adults, HA started 30 minutes to 34 days.
One patient started after 30 minutes; the mean for nine others was 
9 days.20,21,27,28,30,32,33,35,36
•  Fatal HA occurred in 67 percent of 9 children and 30 percent of ten
adults.
•  There is a history of previous ceftriaxone therapy.
•  Positive DATs associated with complement are present in all cases and
additional IgG is present in 75 percent; none had detectable RBC-bound
IgA or IgM.65
•  Antibodies are detected only by immune complex method65 (serum +
drug + RBCs). Some patients’ sera only react with a metabolite of
ceftriaxone (ex vivo antigen).29,32,35
I M M U N O H E M A T O L O G Y, V O L U M E  2 0 , N U M B E R  3 , 2 0 0 4 141
Review: drug-induced hemolytic anemia
DIIHA Associated With Nonimmunologic
Adsorption of Proteins Onto RBCs
RBCs treated with the first-generation cephalo-
sporin, cephalothin, were found to adsorb many
proteins nonimmunologically when incubated in vitro
with normal plasma/sera.74 Such adsorbed proteins led
to a positive AHG test, but it was thought that this was
clinically insignificant, and indeed there were only five
cases of DIIHA due to cephalothin reported in more
than 30 years of use.8–11 Some other drugs have been
found to show a similar phenomenon (see Table 6), but
some of these drugs have been thought to cause DIIHA
more commonly than cephalothin.
Causes for the uptake of protein are not always
clear. Garratty and Petz75 suggested that cephalothin
changed the RBC membrane in a way that created sites
for protein binding. Later this was challenged by
Branch and Petz,76 who suggested that no membrane
change occurred and that protein attached to free
protein binding sites on the cephalothin that had
covalently bonded to proteins on the RBC membrane.
Garratty and Leger77 were stimulated by an old finding,
that cefotetan-treated RBCs were “PNH-like” (e.g., had a
positive acidified serum test).78 To reexamine the issue,
Garratty and Leger77 confirmed these old findings by
showing, using flow cytometry, that cephalothin- and
cefotetan-treated RBCs had markedly decreased
amounts of CD55 and CD58 on the RBC membrane;
CD59 was only slightly decreased. Thus, the results
were different from the changes associated with PNH
but confirmed the original hypothesis of Garratty and
Petz75 that cephalosporins can modify the RBC
membrane. Whether this is the cause of the
nonimmunologic uptake of protein remains to be
proved.
Other drugs have been found to cause non-
immunologic adsorption of proteins onto RBCs (Table
6). Some drugs containing aldehyde groups can bind to
RBC proteins and adsorb proteins from the plasma,
leading to positive AHG tests, but HA has not been
associated with such drugs.79,80
Drugs belonging to the platinum family (e.g.,
cisplatin, carboplatin, and oxaliplatin) have been
associated with positive DATs and HA.81–92 Some
investigators81 have suggested that cisplatin causes
nonimmunologic adsorption of protein and that the
HA is coincidental; others believe the drug can cause
DIIHA. We believe that some patients can develop
antibodies to the drug and that the DIIHA may occur
because of this, regardless of nonimmunologic protein
adsorption. We have described a patient who had
antibodies to oxaliplatin but no HA.92
Nevertheless, I now believe that nonimmunologic
adsorption of protein may lead to HA. This is mainly
based on work we have performed on another family
of drugs, the beta lactamase inhibitors. Examples of
these commonly used drugs are sulbactam (contained
in Unasyn), clavulanate (contained in Augmentin and
Timentin), and tazobactam (contained in Zosyn). They
are used together with the beta lactam antibiotics
ampicillin, ticarcillin, and piperacillin, respectively.
Lutz and Dzik93 reported that 39 percent of patients
receiving Unasyn developed weakly positive DATs but
no HA. We showed later that RBCs treated in vitro with
the beta lactamase inhibitors contained in Unasyn,
Augmentin,Timentin,and Zosyn would adsorb proteins
nonimmunologically, leading to positive IATs, and that
this may be the cause of positive DATs associated with
such drugs. It should be mentioned that patients may
make antibodies to the antibiotics also present in the
drug (e.g., ampicillin,piperacillin), and these antibodies
can cause positive AHG tests and HA. Garratty and
Arndt94,95 suggested that HA could also occur in
patients who have no antibodies to the antibiotics and
that this may be associated with nonimmunologic
adsorption of protein. This suggestion was supported
by case histories and in vitro experiments where it was
shown that RBCs treated with the beta lactamase
inhibitors, washed, and incubated in normal plasma,
washed, and then added to a monocyte monolayer
yielded results suggesting that the RBCs would have
shortened survival.95 Broadberry et al.96 described a
DIIHA associated with tazobactam; the HA was thought
to be due to nonimmunologic adsorption of protein.
Unfortunately, we cannot prove in the laboratory
that this nonimmunologic adsorption of proteins is
causing the HA in a particular patient; one can only
suggest it to the physicians and refer them to the
appropriate literature (e.g., references 6 and 94–96).






sulbactam (contained in Unasyn)
clavulanate (contained in Augmentin and Timentin)
tazobactam (contained in Zosyn)
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Mechanisms of DIIHA
There are two well-accepted mechanisms for
DIIHA, namely, that individuals can produce either
drug-dependent antibodies or drug-independent
antibodies (Table 7). The latter can be classic
autoantibodies in that they do not require drug to be
present for their reaction with RBCs in vitro or in vivo;
drug is only needed to initiate the production of
antibodies. It is still unclear how this occurs, but the
most popular concept is that certain drugs given to
certain patients somehow affect the immune system to
produce pathogenic autoantibodies, as do certain
infections in certain patients. The mechanisms may
turn out to be similar. The AIHA often continues for
some time after the drug is discontinued. Some drug
antibodies (e.g., cefotetan) sometimes react with RBCs
without drug being present, but I do not think that
these are “classic” autoantibodies (in contrast to those
associated with methyldopa). Drug-independent
antibodies (e.g., cefotetan antibodies) are never seen
without the presence of drug-dependent antibodies
and when the drug is stopped, the “autoantibodies”
become weaker, eventually disappearing (see Table 7).
I believe that these antibodies are not produced
because of the drug’s effect on the immune system,but
rather are part of the spectrum of antibodies produced
as a result of the immune response to a hapten (e.g.,
antibodies to the drug, carrier [RBC protein], and drug
+ carrier).97 See Figure 1.
Drug-dependent antibodies can be of two types.
One type of antibody can be inhibited by the drug
(hapten inhibition) and reacts only with washed, drug-
coated RBCs (prototype drug is penicillin). The other
type, which relates to most drugs, is not inhibited by
the drug and reacts with untreated RBCs in the
presence of the drug. We still do not know why. There
have been two main suggestions:
• The drug antibody combines with the drug,
forming immune complexes which attach to the
RBC (transiently) and activate complement.
• The drug changes the RBC membrane,producing
a new antigen (“neoantigen”) as a new epitope.
This neoantigen may be a chemically modified
membrane protein or part drug, part RBC
membrane protein (“compound” epitope).
The latter part of the latter concept  is the basis of
the unifying hypothesis originally  suggested by
Habibi,98 and supported by Mueller-Eckhardt and
Salama,99 which I feel has much merit. Unfortunately,
like other concepts, it has some failings (these are
discussed in references 5, 6, and 99). Although the
immune complex hypothesis is out of favor, the clinical
findings and some serologic data fit much better with
the “immune complex”hypothesis. Shulman and Reid100
tried to take some of the best of both hypotheses, and
suggest some explanations for the discrepancies, but
personally I do not think that, in 2004, we have any
better explanations that we did in 1994!








































*Drugs in groups 1 and 1a have been reported to induce drug-dependent antibodies
only. More evidence is needed to prove that drugs in group 1a really can induce RBC
autoantibodies. Drugs in group 2 induce drug-independent antibodies together with
antibodies reacting by different mechanisms.
Fig. 1. Proposed unifying theory of drug-induced antibody reactions.97
The thicker, darker lines represent antigen-binding sites on the
F(ab) region of the drug-induced antibody. Drugs (haptens) bind
loosely or firmly to cell membranes, and antibodies may be made
to the drug (producing in vitro reactions typical of a drug
adsorption [penicillin-type] reaction; the membrane compo-
nents, or mainly membrane components (producing in vitro
reactions typical of autoantibody); or part-drug, part-membrane
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